Cagrilintide

Cagrilintide is a long-acting acylated amylin analog engineered for extended half-life and once-weekly dosing, designed to activate amylin receptors (AMY1-3) in the area postrema, nucleus tractus solitarius, and hypothalamus — brain regions critical for energy intake regulation, gastric emptying control, and body weight homeostasis.

As a selective amylin receptor agonist, cagrilintide complements GLP-1 receptor agonism through a distinct and additive mechanism — reducing food intake via separate hypothalamic satiety circuits while providing complementary glucoregulatory effects — a mechanistic synergy that has driven its development in combination with semaglutide (as CagriSema).

Research data from Phase 2 and Phase 3 trials have demonstrated that cagrilintide alone and in combination produces meaningful body weight reduction, appetite suppression, and metabolic improvements — establishing it as an important research compound in the next generation of multi-mechanistic weight loss and metabolic therapy investigation.

Specifications:

• Purity: ≥99% (HPLC verified)
• Form: Lyophilized powder
• Storage: −20°C

For Research Use Only.